logo BDSP

Base documentaire


  1. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma : A longitudinal study.

    Article - En anglais

    BACKGROUND

    It has been hypothesized that high androgen levels are determinants of prostate carcinoma.

    METHODS

    Serum concentrations of testosterone, sex hormone-binding globulin (SHBG), and androstenedione were analyzed to determine their role as predictors of prostate carcinoma in a longitudinal, population-based, nested case-control study.

    The serum concentrations of testosterone, SHBG, and androstenedione were determined from serum samples collected by the Finnish Mobile Clinic Health Examination Survey between 1968-1972 and stored at - 20 °C. During a follow-up period of 24 years, a total of 166 prostate carcinoma cases occurred among men who originally were cancer free.

    Two controls (matched for age and municipality) were chosen.

    RESULTS

    There was no association between serum testosterone, SHBG, or androstenedione concentrations and the occurrence of subsequent prostate carcinoma in the total study population or in subgroups determined based on age or body mass index.

    The association was not strengthened by simultaneous adjustment for the hormonal variables.

    CONCLUSIONS

    The results of the current study do not appear to corroborate the hypothesis that serum testosterone, SHBG, or androstenedione are determinants of the subsequent occurrence of prostate carcinoma.

    Mots-clés Pascal : Carcinome, Prostate, Facteur risque, Androstènedione, Epidémiologie, Testostérone, Globuline, Protéine liaison hormone stéroïde sexuelle, Etude cas témoin, Finlande, Europe, Homme, Tumeur maligne, Prostate pathologie, Appareil urinaire pathologie, Appareil génital mâle pathologie, Hormone stéroïde sexuelle, Androgène

    Mots-clés Pascal anglais : Carcinoma, Prostate, Risk factor, Androstenedione, Epidemiology, Testosterone, Globulin, Sex hormone binding protein, Case control study, Finland, Europe, Human, Malignant tumor, Prostate disease, Urinary system disease, Male genital diseases, Sex steroid hormone, Androgen

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0391687

    Code Inist : 002B14D02. Création : 22/03/2000.